PAM
PETX

Princeton Alpha Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Princeton Alpha Management’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-11,751
Closed -$74K – 1028
2016
Q2 		$74K Buy
+11,751
New +$75.6K 0.01% 737

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Princeton Alpha Management's PETX Position: Q3 2016 in Review

Princeton Alpha Management sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2016, closing a stake of 11,751 shares — an estimated $74K sold.

Princeton Alpha Management first reported a position in PETX in Q2 2016 and held it in 1 quarter. The position peaked at $74K in Q2 2016. 128 funds tracked by Wall St. Rank hold PETX as of Q3 2016.

  • Princeton Alpha Management reported no remaining Aratana Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Princeton Alpha Management sold 11,751 Aratana Therapeutics, Inc. shares in Q3 2016, an estimated $74K.
  • Princeton Alpha Management first reported a position in Aratana Therapeutics, Inc. in Q2 2016 and held it in 1 quarter.
  • Princeton Alpha Management's Aratana Therapeutics, Inc. position peaked at $74K in Q2 2016.
  • 128 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2016.

Based on Princeton Alpha Management's 13F filing for Q3 2016, filed 10 Nov 2016.